Journey Medical Corporation Enters into a Definitive Agreement with Dr. Reddy’s Laboratories Ltd. to Develop and Commercialize DFD-29 for the Treatment of Rosacea

Source: GlobeNewswire Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced an agreement with Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) for the collaborative development and commercialization of the DFD-29 program (Minocycline Modified Release Capsules 40 mg) for the treatment of rosacea. Journey…...